Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.
Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.
Keep up to date on our investments and business developments in recent news stories and summaries.
December 5, 2022 – Your friends at FACIT wish you a healthy and relaxing holiday season. It has been a productive year and our team continues to grow the province’s biotech ecosystem through the commercialization of Ontario’s most promising cancer innovations.
September 28, 2022 – September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.
June 16, 2022 – The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.
Read More from FACIT’s David O’Neill shares strategy for Ontario intellectual property
We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives.
FACIT is funded in part by the Government of Ontario through OICR